The pharmaceutical Sector is booming again! AKESO's stock has risen over 9%, reaching a new historical high, with Goldman Sachs stating that the global capital re-evaluation of Chinese innovative drugs has just begun.

On July 17, Gelonghui reported that the Medical Sector continued to surge strongly today, with the Hong Kong stocks of innovative drug companies leading the way. AKESO, a global pioneer and best-in-class dual antibody drug R&D company, rose more than 9% to hit a new historical high. SKB BIO-B and 3SBIO both rose over 9% and 7% respectively, also reaching new historical highs, while BEIGENE increased by more than 7%, and GENSCRIPT BIO, TIGERMED, and others rose over 4%. In news: ① SINO BIOPHARM announced a major acquisition of Lixin Pharmaceutical! On July 15, SINO BIOPHARM announced that the company acquired Lixin Pharmaceutical through a wholly-owned subsidiary, with a transaction price not exceeding $0.95092 billion. ② The 11th batch of national organized drug procurement has been initiated, and innovative drugs are not included in this procurement. Regarding capital flow: ③ Southbound funds continue to net buy AKESO; this stock has made the list of the top ten most active stocks in three instances in July, with a net buying of HK$0.129 billion yesterday. Goldman Sachs previously noted that the overall Market Cap of Chinese biotech companies is still only 14%-15% of their American counterparts, while their share of global innovation contributions is approaching 33%. This means that the Chinese innovative drug sector is still in a "value pit" phase, and the global capital reassessment has just begun. Notable products and their changes as of the time of writing: The CSI Health Care ETF (159892), which represents the global full industry chain of pharmaceuticals, rose 3.6% as of the time of writing and has accumulated a rise of over 73.24% year-to-date. It tracks the Hang Seng Biotech Index, and the top ten weighted stocks include several innovative companies that have reached new highs: BEIGENE (9.09%), WUXI BIO (9.08%), AKESO (7.66%), SINO BIOPHARM (6.01%), and 3SBIO (4.84%). The Star Medical ETF Fund (588130), which represents the Star in biomedicine, rose 1.84% as of the time of writing and covers areas including innovative drugs and medical devices. The top ten constituent stocks include leading companies such as United Imaging Healthcare, BEIGENE, BGI Genomics, and JUNSHI BIO.